Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin presented as an injectable solution (powder for solution for injection) for intramuscular and subcutaneous use. It provides both FSH and LH activity to treat infertility due to anovulation and to support controlled ovarian stimulation in assisted reproductive technology.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menopur is a gonadotropin used in reproductive medicine to stimulate ovarian follicular development.

Anovulation (including polycystic ovary syndrome): promotes follicular growth to enable ovulation. Assisted reproductive technology (IVF, ICSI): supports controlled ovarian stimulation to obtain multiple mature oocytes. Ovarian stimulation for egg donation programs: enhances follicular response to increase oocyte yield.

Menopur may cause a range of adverse reactions, most of which are related to its hormonal activity and the injection route.

Common Side Effects: - Injection site pain or erythema - Abdominal discomfort or bloating - Mild ovarian hyperstimulation syndrome (OHSS) - Headache - Nausea or vomiting - Breast tenderness

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome - Thromboembolic events (blood clots) - Allergic reactions including anaphylaxis - Ovarian cyst rupture or hemorrhage - Multiple pregnancy (high-order twins or more) - Severe abdominal pain indicating intra‑abdominal bleeding

Before initiating Menopur therapy, several safety considerations should be observed.

Pregnancy testing before start: confirm the patient is not pregnant. Monitor ovarian response with ultrasound: adjust dose based on follicular growth. Avoid in known hypersensitivity to menotropin or any excipients. Use caution in patients with existing ovarian cysts or endocrine disorders. Avoid in uncontrolled thyroid disease. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other hormonal agents and medications that affect coagulation or endocrine balance.

Major Interactions (Avoid): - GnRH agonist therapy: may blunt ovarian response. - Concomitant use of hCG before the follicular phase: may cause premature luteinization. - Estrogen‑containing oral contraceptives during stimulation: reduces efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of ovarian bleeding. - Thyroid hormone therapy: may alter ovarian response to stimulation.